world
Trial for Bundibugyo Ebola treatment starts in DRC, WHO says
The trial will evaluate Mapp Biopharmaceutical's experimental MBP134 antibody as a standalone treatment for Bundibugyo Ebola, as well as in combination with Gilead Sciences' antiviral drug remdesivir, the WHO said
Read full article at source ↗Related news
What triggered the mass migrant crossings into Ceuta?
India risks complicity in Israel’s war crimes in Gaza, Amnesty report reveals
U.S. lawmaker urges Taiwan to pass drone Bill, warning 'time is short'
Myanmar's President outlines policy road map, criticises ASEAN peace plan
Spain's PM blames Ceuta migrant influx on criminal networks manipulating recent court ruling
What's in the Gaza peace deal roadmap?
India calls for global scrutiny over Pakistan’s ‘ruthless’ crackdown in PoK
Bowen: Plan for Hamas to disarm faces big obstacles, yet it offers rare hope for Gaza